Cardiac cell proliferation is not necessary for exercise-induced cardiac growth but required for its protection against ischaemia/reperfusion injury

Yihua Bei a, Siyi Fu a, Xiangming Chen a, b, Mei Chen a, c, Qiulian Zhou a, Pujiiao Yu d, Jianhua Yao e, Hongbao Wang e, Lin Che d, Jiahong Xu d, Junjie Xiao a, *

a Cardiac Regeneration and Ageing Lab, School of Life Science, Shanghai University, Shanghai, China
b Department of Clinical laboratory, Nanxiang Hospital of Jiading, Shanghai, China
c Department of Geriatrics, Xuhui Central Hospital, Shanghai Clinical Center, Chinese Academy of Science, Shanghai, China
d Department of Cardiology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China
e Department of Cardiology, Shanghai Yangpu District Hospital, Tongji University School of Medicine, Shanghai, China

Received: June 12, 2016; Accepted: November 29, 2016

Abstract

The adult heart retains a limited ability to regenerate in response to injury. Although exercise can reduce cardiac ischaemia/reperfusion (I/R) injury, the relative contribution of cardiac cell proliferation including newly formed cardiomyocytes remains unclear. A 4-week swimming murine model was utilized to induce cardiac physiological growth. Simultaneously, the antineoplastic agent 5-fluorouracil (5-FU), which acts during the S phase of the cell cycle, was given to mice via intraperitoneal injections. Using EdU and Ki-67 immunolabelling, we showed that exercise-induced cardiac cell proliferation was blunted by 5-FU. In addition, the growth of heart in size and weight upon exercise was unaltered, probably due to the fact that exercise-induced cardiomyocyte hypertrophy was not influenced by 5-FU as demonstrated by wheat germ agglutinin staining. Meanwhile, the markers for pathological hypertrophy, including ANP and BNP, were not changed by either exercise or 5-FU, indicating that physiological growth still developed in the presence of 5-FU. Furthermore, we showed that CITED4, a key regulator for cardiomyocyte proliferation, was blocked by 5-FU. Meanwhile, C/EBPβ, a transcription factor responsible for both cellular proliferation and hypertrophy, was not altered by treatment with 5-FU. Importantly, the effects of exercise in reducing cardiac I/R injury could be abolished when cardiac cell proliferation was attenuated in mice treated with 5-FU. In conclusion, cardiac cell proliferation is not necessary for exercise-induced cardiac physiological growth, but it is required for exercise-associated protection against I/R injury.

Keywords: exercise ● proliferation ● 5-fluorouracil ● ischaemia/reperfusion injury

Introduction

Exercise is now accepted as a useful therapeutic strategy for cardiovascular diseases [1]. Although similar in morphological level to pathological hypertrophy, exercise-induced cardiac growth has distinct cellular and molecular mechanisms [2]. Substantially, the adult mammalian heart has some endogenous regenerative capacity which could be enhanced by exercise [3]. However, the contribution of cardiomyocyte renewal to the benefit of exercise upon cardiac injury is largely unknown [4].

Various studies have reported that exercise can attenuate cardiac I/R injury [5, 6]. The cardiac cell death due to apoptosis and necrosis represents key cellular responses upon myocardial I/R injury [7]. Exercise was demonstrated to reduce cardiomyocyte apoptosis in a PI3 kinase- and Akt-dependent manner [8]. The anti-apoptosis effect on cardiomyocytes is also linked to enhanced antioxidative defence and mitochondrial adaptions upon exercise [9–11]. Meanwhile, exercise is able to improve myocardial glucose and fatty acid metabolism during I/R injury [12]. Noteworthy, exercise-induced cardiomyocyte renewal is supposed to be able to partly make up the cell loss during cardiac I/R injury, although the relative contribution has not yet been elucidated [13].

In this study, we utilized a mouse swimming exercise model to induce cardiac physiological growth. Simultaneously, the antineoplastic agent 5-FU, which acts during the S phase of the cell cycle by inhibiting DNA synthesis and reducing cell proliferation,
was given to mice via intraperitoneal injections. This study aimed firstly to clarify whether cardiac cell proliferation is necessary for exercise-induced cardiac growth at both cellular and molecular levels, and then to elucidate whether or to what extent cardiac cell proliferation contributes to the protective effect of exercise against cardiac I/R injury.

**Materials and methods**

**Animals**

Male C57BL/6 mice aged 8 weeks were purchased from the Animal Research Center of Fudan University (Shanghai, China) and maintained in SPF laboratory Animal Facility of Shanghai University (Shanghai, China). All animal experiments were conducted under the guidelines on the use and care of laboratory animals for biomedical research published by National Institutes of Health. The study was approved by the committee on the Ethics of Animal Experiments of Shanghai University.

**Mouse swimming protocol**

Adult male C57BL/6 mice were submitted to a 4-week swimming exercise to induce cardiac physiological growth [13]. Briefly, mice received a swimming protocol which started from 5 min. twice for the first day and 10 min. twice for the second day, and then continued with an increase of 10 min. per day until 90 min. twice per day reached. After 4 weeks of exercise training, mice were killed and tissues were collected. The heart weight (HW), heart weight/body weight ratio (HW/BW) and heart weight/tibia length ratio (HW/TL) were calculated to evaluate cardiac growth after exercise.

**Cardiac I/R model**

By the day of the last swimming session, cardiac I/R injury was induced by 30 min. of coronary artery ligation followed by 24 hrs of cardiac reperfusion as previously described [14]. Briefly, the left anterior descending artery (LAD) was ligated with 8-0 silk in anesthetized mouse. After 30 min. of LAD occlusion, the ligation was relieved. Twenty-four hours after reperfusion, mice were killed and hearts were stained with 1% TTC in phosphate-buffered saline (PBS) at 37°C for 10 min. After fixed with 4% paraformaldehyde (PFA), images were taken under light microscope and analysed with IMAGEJ software (National Institutes of Health). The cardiomyocyte size was determined by the measurement of total area divided by the number of cardiomyocytes.

**5-FU and EdU injections**

As we do not have a method to specifically inhibit cardiomyocyte proliferation, we investigated whether cardiac cell proliferation was necessary for exercise-induced cardiac growth and to what extent it contributed to the cardiac protective effect of exercise. 5-FU injection was performed in the present study to block cell proliferation. Briefly, mice were intraperitoneally injected with 5-FU (10 mg/kg; Sigma-Aldrich, St. Louis, MO, USA) every 5 days for five cycles, starting from the third day of swimming training [16]. The control mice were injected with PBS instead. For mice enrolled for EdU incorporation assay, 5-ethyl-2'-deoxyuridine (EdU, 50 mg/kg; Invitrogen, Carlsbad, CA, USA) was intraperitoneally injected to mice the day before killing.

**EdU and Ki-67 immunofluorescent staining**

The 5-µm-thick frozen sections of heart tissues were fixed with 4% PFA for 15 min. and washed with PBS for three times. Next, the heart sections were treated with 0.5% Triton X-100 for 20 min., and then blocked in 3% bovine serum albumin (BSA) for 1 hr at room temperature. Afterwards, the sections were incubated with rabbit polyclonal Ki-67 primary antibody (ab15580, 1:100 dilution; Abcam, Cambridge, MA, USA) overnight at 4°C. After washed with PBS, the sections were incubated with goat anti-rabbit/FITC secondary antibody (111-095-003, Jackson, West Grove, PA, USA) for 2 hrs at room temperature in darkness. The sections were then washed with PBS and incubated with EdU (Alexa Fluor® 647, 1529380; Invitrogen) for 30 min. Finally, the sections were mounted with Prolong Gold containing DAPI (P36941; Invitrogen) and kept at 4°C in darkness. The confocal laser scanning microscope (LSM 710; Carl Zeiss, Jena, Germany) was used to observe the EdU-positive cells and Ki-67-positive cells which determined cell proliferative rate in heart tissues.

**Wheat germ agglutinin (WGA) staining**

The 5-µm-thick frozen heart sections were fixed with 4% PFA for 15 min. and then washed with PBS for three times. Next, the heart sections were incubated with WGA (L4895; Sigma-Aldrich) solubilized in PBS for 20 min. at room temperature in darkness. After washed three times with PBS, the sections were mounted with Prolong Gold containing DAPI (P36941; Invitrogen) and kept at 4°C in darkness. The confocal laser scanning microscope (LSM 710; Carl Zeiss) was used to examine the cardiomyocyte size. A total of 30 fields per section were observed at 400× magnification and analysed with IMAGEJ software (National Institutes of Health). The cardiomyocyte size was determined by the measurement of total area divided by the number of cardiomyocytes.

**RNA extraction and qRT-PCR**

Total RNA were extracted from heart tissues using RNAiso Plus Total RNA extraction reagent (Takara, Kusatsu, Japan) according to the manufacturer’s instruction. Then, 400 ng of total RNA was reverse-transcribed into cDNA using Prime Script II First Strand cDNA Synthesis Kit (Takara). The quantitative PCR was then performed with PCR primers and SYBR Green (Takara) for 40 cycles in
CFX96™ Real-Time PCR Detection System (Bio-Rad, Berkeley, CA, USA). The primer sequences used are as follows (5’–3’): ANP (forward: TGA CAG GAT TGG AGC CCA GAG and reverse: AGC TGC GTG ACA CAC CAC AAG) and BNP (forward: GCT GCT TTG GGC ACA AGA TAG and reverse: GGT CTT CCT ACAACA ACT TCA). The GAPDH (forward: 5’–3’ AGG TCG GTG TGA ACG GAT TTG and reverse: TGT AGA CCA TGT AGT TGA GGT CA) was used for normalization. The relative expression levels of ANP and BNP were calculated using the $2^{-\Delta\Delta CT}$ method.

Western blot analysis

Heart tissues were lysed in RIPA buffer with 1% PMSF and Pierce™ protease and phosphatase inhibitor (88668; Thermo, Waltham, MA, USA). The equal amount of total proteins was separated in 10% SDS-PAGE gel and then transferred onto PVDF membrane. After blocked in 5% BSA for 2 hrs at room temperature, the membranes were blotted with mouse monoclonal anti-CITED4 (ab77018, 1:1000 dilution; Abcam) and mouse monoclonal anti-C/EBPβ (ab15050, 1:1000 dilution; Abcam) primary antibodies at 4°C overnight. The GAPDH (AP0063, 1:1000 dilution; Bioworld, St. Louis Park, MN, USA) was used as a loading control. The membranes were then washed with PBS and incubated with proper secondary antibodies for 2 hrs at room temperature. Then, the protein bands were visualized via enhanced chemiluminescence (ECL) kit in ChemiDoc XRS Plus luminescent image analyser (Bio-Rad), and then quantified with IMAGE LAB software (Bio-Rad).

Statistical analysis

All data were analysed with SPSS software (Version 19.0) (International Business Machines Corporation, Armonk, NY, USA) and presented as mean ± S.E.M. The one-way ANOVA followed by Bonferroni’s post hoc test was conducted to determine groups with significant difference. A P-value less than 0.05 was considered statistically significant.

Results

Exercise-induced cardiac growth is not influenced by inhibition of cell proliferation

In this study, a 4-week swimming exercise induced marked cardiac growth, as demonstrated by enlarged general heart size (Fig. 1A) and increased HW (Fig. 1B). Exercise also slightly reduced body weight (Fig. 1C), while tibia length remained unchanged (Fig. 1D). Indeed, an increase in the HW/BW ratio and HW/TL ratio was detected in exercised mice (Fig. 1E and F). To clarify whether cardiac cell proliferation is necessary for exercise-induced cardiac growth, 5-FU was intraperitoneally injected to mice which caused inhibition of cell proliferation. Importantly, exercise-induced morphological cardiac growth, as well as increased HW/BW ratio and HW/TL ratio, was not influenced by treatment with 5-FU (Fig. 1). These data indicate that exercise-induced cardiac growth still develops when the proliferation of cardiac cells is inhibited by 5-FU.

Exercise-induced cardiac cell proliferation is blunted by 5-FU

Next, we examined both cardiomyocyte hypertrophy and proliferation upon exercise in the presence or absence of 5-FU treatment. As demonstrated by EdU and Ki67 staining, a significant increase in EdU-positive and Ki67-positive cells was detected in the exercised heart,
suggesting that exercise could promote cell proliferation in the heart (Fig. 2A). However, the increased cell proliferation in the exercised heart was significantly reduced by treatment with 5-FU (Fig. 2A). On the contrary, exercise-associated enlargement in cardiomyocyte size was not altered in 5-FU-treated mice as assessed by WGA staining (Fig. 2B).

Cardiac cell proliferation is not necessary for exercise-induced cardiac physiological growth

Besides direct detection of cardiac cell proliferation by EdU and Ki-67 staining, the expression levels of C/EBPβ and CITED4 were also determined. The down-regulated transcription factor C/EBPβ and
subsequent activation of CITED4 have previously been reported as critical molecular mechanisms responsible for exercised-induced cardiac growth [3]. Consistently, here we found that C/EBPβ was downregulated, while CITED4 was up-regulated in the exercised heart (Fig. 3A). Notably, the exercise-associated activation of CITED4, a key regulator for cardiomyocyte proliferation, was blocked by 5-FU (Fig. 3A). While exercise-induced reduction of C/EBPβ, a transcription factor responsible for both cellular proliferation and hypertrophy, was not altered by treatment with 5-FU (Fig. 3A). To determine whether exercise-induced cardiac growth is still physiological when cardiac cell proliferation is inhibited, two typical markers for pathological hypertrophy including ANP and BNP were determined and both were not elevated in the exercised heart, regardless of 5-FU treatment (Fig. 3B and C).

Cardiac cell proliferation is required for the protective effect of exercise against cardiac I/R injury

To further investigate whether exercise-induced cardiac cell proliferation is essential for the cardioprotective effect of exercise, sedentary or exercised mice were submitted to cardiac I/R injury with or without 5-FU treatment. Twenty-four hours after I/R injury, mice hearts were submitted to TTC staining which demonstrated that the infarct size/area at risk (INF/AAR) ratio was significantly reduced in exercised mice, while the protective effect of exercise was totally abolished by treatment with 5-FU (Fig. 4). Thus, we suggest that exercise-induced cell proliferation in the heart, at least partly associated with newly formed cardiomyocytes, is an indispensable mechanism which mediates the beneficial effect of exercise upon myocardial injury.

Discussion

The novel finding of our study is that reduced cardiac cell proliferation due to 5-FU treatment does not affect exercise-induced cardiac growth and the expression levels of ANP and BNP, indicating that increased cardiac cell proliferation is not necessary for exercise-induced cardiac physiological growth. However, exercise-associated cardiac cell proliferation is a requirement for the protective effect of exercise against cardiac I/R injury.

Exercise-induced physiological cardiac growth is similar in general morphological level to pathological cardiac remodelling, with the increase in both heart size and HW [17, 18]. However, cellular adaptations of cardiac growth in response to exercise are notably distinct from those in pathological conditions [19, 20]. The adult mammalian heart retains a limited regeneration capacity, which can be enhanced by exercise training [21–24]. Although increasing evidence indicates that exercise-induced cardiac growth is achieved by both

![Image](https://example.com/image.png)
Cardiomyocyte hypertrophy and formation of new cardiomyocytes, little is known about to what extent these newly formed cardiomyocytes contribute to exercise-induced cardiac growth. Here we used 5-FU, a widely used antineoplastic agent, to inhibit exercise-induced cardiac cell proliferation including the formation of new cardiomyocytes. It is also worth noting that the proliferation rate of cardiac cells, although not statistically significant, demonstrated a trend to be reduced by 5-FU in sedentary mice. We suggested that this phenomenon might be linked to the very low proliferation rate of adult cardiac cells at baseline [13]. Interestingly, here we found that the HW/BW and HW/TL ratios of swum mice were still increased in the presence of 5-FU due to the fact that exercise-associated increase in cardiomyocyte size was not affected, indicating that exercise-induced cardiac growth still developed. Moreover, the fact that the expression levels of ANP and BNP were not changed by 5-FU in swum mice further confirmed that the cardiac growth was physiological. Collectively, this study shows that cardiac cell proliferation including newly formed cardiomyocytes is not necessary for exercise-induced cardiac physiological growth.

It was previously reported that reduced C/EBPβ and subsequent increased CITED4 contribute to exercise-induced cardiac growth [3]. Reduction of C/EBPβ in vivo and in vitro leads to both hypertrophy and proliferation of cardiomyocytes [3]. C/EBPβ was also demonstrated to exert its antiproliferative effect via inhibition of CITED4 [3]. Interestingly, increased expression of CITED4 is able to activate cyclin D1, thus promoting cardiomyocyte proliferation [25]. Here we showed that C/EBPβ was reduced while CITED4 was increased in swum mice heart, which is consistent with the previous report [3]. Importantly, exercise-associated molecule expression change of CITED4, but not of C/EBPβ, was blocked by 5-FU. We suggested that this might be due to the fact that CITED4 is preferentially a key regulator for cardiomyocyte proliferation, while C/EBPβ is responsible for both hypertrophy and proliferation of cardiomyocytes [3].

The adult heart has an endogenous limited regeneration capacity in response to exercise, and exercise can protect myocardial injury [26, 27]. Exercise was reported to reduce the apoptosis of cardiomyocytes, enhance mitochondrial biogenesis and improve myocardial energy metabolism, thus leading to cardioprotection against I/R injury [13, 28, 29]. However, little is known about to what extent cardiac cell proliferation, including formation of new cardiomyocytes, contributes to the cardioprotective effect of exercise. Our data demonstrate that the benefit of exercise in reducing cardiac I/R injury could be abolished by 5-FU treatment, highly suggesting that increased cardiac cell proliferation in response to exercise is essential to achieve the cardioprotective effect of exercise upon I/R injury.

One limitation of the present study is that the inhibitory effect of 5-FU on cell proliferation is systemic and non-cell type specific.
This means that in addition to the inhibition of formation of new cardiomyocytes, the proliferation of other cell types could be reduced in the exercised heart with 5-FU treatment. The cardiomyocyte renewal upon exercise may be linked to the proliferation of pre-existing cardiomyocytes and the activation and differentiation of cardiac progenitor/stem cells [3, 23, 24, 30]. Moreover, the bone marrow-derived endothelial progenitor cells (EPCs) can also be recruited into systemic circulation in response to exercise, and mobilized to the heart where they contribute to endothelial renewal [31–33]. Thus, the reduced cardiac cell proliferation in 5-FU-treated exercised heart as well as the loss of protective effect of exercise against I/R injury might also be attributable to the reduction of proliferation of other types of cells. Another limitation is that cardiac function was not directly assessed in this study. As 5-FU has previously been associated with some degree of cardiac toxicity, the potential cardiotoxicity of this agent should be taken into account [34]. However, we consider this unlikely in the current study for a number of reasons. First, it was previously demonstrated that a similar 5-FU protocol was not associated with any cellular or functional cardiotoxic effects [16]. Second, the frequency and duration of 5-FU treatment in the present study were different from other studies reporting the cardiotoxicity of this agent [35, 36]. Third, there was no elevation of ANP or BNP expression in control or swim mice receiving 5-FU.

In conclusion, this study demonstrates that increased cardiac cell proliferation is not necessary for exercise-induced cardiac physiological growth. However, cardiac cell proliferation is a requirement to achieve exercise-associated cardioprotection against I/R injury.

Acknowledgements

This work was supported by the grants from National Natural Science Foundation of China (81570362, 81200109 and 91639101 to J.X., 81470515 and 81270314 to J.X., 81472158 to L.C., 81541007 to H.W., 81400647 to Y.B.), Innovation Program of Shanghai Municipal Education Commission (13YZ04 to J.X.), Innovation fund from Shanghai University (sdcx2012038 to J.X.), Program for the integration of production, teaching and research for University Teachers supported by Shanghai Municipal Education Commission (year 2014, to J.X.), Natural Science Foundation of Shanghai (to H.W.; to L.C.) and Shanghai Medical Guide Project from Shanghai Science and Technology Committee (134119a3000 to JH Xu) and the development fund for Shanghai talents (to JJ Xiao).

Conflict of interest

The authors declare there are no conflict of interests.

References

1. Bei Y, Zhou Q, Sun Q, et al. Exercise as a platform for pharmacotherapy development in cardiac diseases. Curr Pharm Des. 2015; 21: 4409–16.
2. Ellison GM, Waring CD, Vicinanza C, et al. Physiological cardiac remodelling in response to endurance exercise training: cellular and molecular mechanisms. Heart. 2012; 98: 5–10.
3. Bosstrom B, Mann N, Wu J, et al. CE/EBPbeta controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell. 2010; 143: 1072–83.
4. Rosenzweig A. Medicine. Cardiac regeneration. Science. 2012; 338: 1549–50.
5. Quindry JC, Hamilton KL, French JP, et al. Exercise-induced HSP-72 elevation and cardioprotection against infarct and apoptosis. J Appl Physiol. 2007; 103: 1056–62.
6. Calvert JW, Condit ME, Aragon JP, et al. Exercise protects against myocardial ischemia-reperfusion injury via stimulation of beta(3)-adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols. Circ Res. 2011; 108: 1448–56.
7. Santos-Gallego CG, Vahl TP, Goliash G, et al. Sphingosine-1-Phosphate receptor agonist Fingolimod increases myocardial salvage and decreases adverse Postinfarction left ventricular remodeling in a Porcine Model of Ischemia/Reperfusion. Circulation. 2016; 133: 954–66.
8. Zhang KR, Liu HT, Zhang HF, et al. Long-term aerobic exercise protects the heart against ischemia/reperfusion injury via PI3 kinase-dependent and Akt-mediated mechanism. Apoptosis. 2007; 12: 1579–88.
9. Frasier CR, Moukarf F, Patel HD, et al. Redox-dependent increases in glutathione reductase and exercise preconditioning: role of NADPH oxidase and mitochondria. Cardiovasc Res. 2013; 98: 47–55.
10. French JP, Hamilton KL, Quindry JC, et al. Exercise-induced protection against myocardial apoptosis and necrosis: MnSOD, calcium-handling proteins, and calpain. FASEB J. 2008; 22: 2862–71.
11. Lee Y, Min K, Talbert EE, et al. Exercise protects cardiac mitochondria against ischemia-reperfusion injury. Med Sci Sports Exerc. 2012; 44: 397–405.
12. Bereule Y, Wambolt RB, Grist M, et al. Regular exercise is associated with a protective metabolic phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2004; 287: H1055–63.
13. Liu X, Xiao J, Zhu H, et al. miR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell Metab. 2015; 21: 584–95.
23. Xiao J, Xu T, Li J, et al. Exercise-induced physiological hypertrophy initiates activation of cardiac progenitor cells. *Int J Clin Exp Pathol*. 2014; 7: 663–9.

24. Waring CD, Vicinanza C, Papalamprou A, et al. The adult heart responds to increased workload with physiologic hypertrophy, cardiac stem cell activation, and new myocyte formation. *Eur Heart J*. 2014; 35: 2722–31.

25. Campa VM, Gutierrez-Lanza R, Cerignoli F, et al. Notch activates cell cycle reentry and progression in quiescent cardiomyocytes. *J Cell Biol*. 2008; 183: 129–41.

26. Puhl SL, Muller A, Wagner M, et al. Exercise attenuates inflammation and limits scar thinning after myocardial infarction in mice. *Am J Physiol Heart Circ Physiol*. 2015; 309: H345–59.

27. Xiao J, Chen P, Qu Y, et al. Telocytes in exercise-induced cardiac growth. *J Cell Mol Med*. 2016; 20: 973–9.

28. Tao L, Bei Y, Zhang H, et al. Exercise for the heart: signaling pathways. *Oncotarget*. 2015; 6: 20773–84.

29. Tao L, Bei Y, Lin S, et al. Exercise training protects against acute myocardial infarction via improving myocardial energy metabolism and mitochondrial biogenesis. *Cellular Physiol Biochem*. 2015; 37: 162–75.

30. Leri A, Kajstura J, Anversa P. Role of cardiac stem cells in cardiac pathophysiology: a paradigm shift in human myocardial biology. *Circ Res*. 2011; 109: 941–61.

31. De Biase C, De Rosa R, Luciano R, et al. Effects of physical activity on endothelial progenitor cells (EPCs). *Front Physiol*. 2013; 4: 414.

32. Ribeiro F, Ribeiro IP, Alves AJ, et al. Effects of exercise training on endothelial progenitor cells in cardiovascular disease: a systematic review. *Am J Phys Med Rehabil*. 2013; 92: 1020–30.

33. Galasso G, De Rosa R, Ciccarelli M, et al. Beta2-Adrenergic receptor stimulation improves endothelial progenitor cell-mediated ischemic neoangiogenesis. *Circ Res*. 2013; 112: 1026–34.

34. Madeddu C, Deidda M, Piras A, et al. Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. *J Cardiovasc Med (Hagerstown)*. 2016; 17: e12–8.

35. Focaccetti C, Bruno A, Magnani E, et al. Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. *PLoS One*. 2015; 10: e0115686.

36. Aikemu A, Amat N, Yusup A, et al. Attenuation effect of Abnormal Savda Munziq on liver and heart toxicity caused by chemotherapy in mice. *Exp Ther Med*. 2016; 12: 384–90.